Compare RZLT & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RZLT | QTRX |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.4M | 306.0M |
| IPO Year | N/A | 2017 |
| Metric | RZLT | QTRX |
|---|---|---|
| Price | $3.31 | $6.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | $9.14 | ★ $11.33 |
| AVG Volume (30 Days) | ★ 4.6M | 723.9K |
| Earning Date | 02-10-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $130,203,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $28.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.07 | $4.05 |
| 52 Week High | $11.46 | $9.92 |
| Indicator | RZLT | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 47.44 |
| Support Level | $2.69 | $6.40 |
| Resistance Level | $3.59 | $7.05 |
| Average True Range (ATR) | 0.28 | 0.64 |
| MACD | 0.27 | -0.08 |
| Stochastic Oscillator | 75.71 | 16.39 |
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.